Clinical Trial Update: A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase I study evaluating ganetespib with or without bortezomib in relapsed/refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Ganetespib (ganetespib)
• Velcade (bortezomib)

Snippet

Sponsor: Emory University | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED